Several inhibitors targeting BRAF and MEK have been deployed in patients with metastatic NSCLC harboring BRAF V600E mutations [131], patients with unresectable or metastatic melanoma harboring BRAF V600E/K mutations [132] and patients diagnosed with anaplastic thyroid cancer carrying BRAF V600E mutations [133]. Here, BRAF is linked to metastatic melanoma.